PKO Investment Management Joint Stock Co Invests $1.97 Million in Insmed, Inc. $INSM

Key Points

• PKO Investment Management acquired a new stake of 11,300 shares in Insmed (NASDAQ:INSM) during Q4, valued at approximately $1.97 million.
• Wall Street maintains an average "Buy" consensus with a consensus price target of $213.23, well above the recent open of $133.26, indicating substantial analyst upside.
• Company insiders have been net sellers—CEO sold 10,699 shares at $143.97 and the COO sold 88,060 shares at $164.63 (179,777 shares worth $28.25M sold last quarter)—and Insmed recently missed EPS (-$1.54 vs. -$1.07) despite revenue rising 152.6% year‑over‑year.

PKO Investment Management Joint Stock Co acquired a new stake in Insmed, Inc. (NASDAQ:INSM - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 11,300 shares of the biopharmaceutical company's stock, valued at approximately $1,967,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in Insmed by 13.0% during the 3rd quarter. Vanguard Group Inc. now owns 19,935,820 shares of the biopharmaceutical company's stock valued at $2,870,957,000 after acquiring an additional 2,291,328 shares during the period. Artisan Partners Limited Partnership increased its stake in Insmed by 49.0% during the third quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company's stock worth $711,076,000 after purchasing an additional 1,623,342 shares during the period. Orbis Allan Gray Ltd purchased a new stake in Insmed during the second quarter worth about $153,389,000. Darwin Global Management Ltd. lifted its position in shares of Insmed by 5.8% during the third quarter. Darwin Global Management Ltd. now owns 20,457,445 shares of the biopharmaceutical company's stock worth $2,897,797,000 after purchasing an additional 1,112,824 shares in the last quarter. Finally, Bank of Nova Scotia purchased a new position in shares of Insmed in the third quarter valued at approximately $72,904,000.

Wall Street Analyst Weigh In

INSM has been the subject of a number of research reports. Truist Financial set a $205.00 price objective on shares of Insmed in a report on Monday, January 12th. Jefferies Financial Group started coverage on shares of Insmed in a research report on Monday, March 16th. They issued a "buy" rating and a $228.00 price target for the company. Morgan Stanley upgraded shares of Insmed from an "equal weight" rating to an "overweight" rating and boosted their price target for the stock from $166.00 to $212.00 in a research note on Monday, March 30th. Royal Bank Of Canada upped their price objective on Insmed from $212.00 to $216.00 and gave the stock an "outperform" rating in a research report on Tuesday, April 14th. Finally, Leerink Partners lifted their target price on Insmed from $210.00 to $215.00 and gave the company an "outperform" rating in a report on Tuesday, March 24th. Two analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $213.23.

Insmed Trading Down 2.3%

NASDAQ:INSM opened at $133.26 on Friday. Insmed, Inc. has a 1 year low of $63.81 and a 1 year high of $212.75. The stock has a market cap of $28.76 billion, a P/E ratio of -20.79 and a beta of 0.90. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.54 and a current ratio of 3.83. The stock has a 50-day simple moving average of $147.89 and a 200-day simple moving average of $166.21.

Insmed (NASDAQ:INSM - Get Free Report) last posted its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.47). The business had revenue of $263.84 million for the quarter, compared to analysts' expectations of $263.97 million. Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.Insmed's revenue for the quarter was up 152.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.32) EPS. As a group, analysts anticipate that Insmed, Inc. will post -2.51 earnings per share for the current fiscal year.

Insider Transactions at Insmed

In related news, CEO William Lewis sold 10,699 shares of Insmed stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $143.97, for a total transaction of $1,540,335.03. Following the sale, the chief executive officer directly owned 301,185 shares in the company, valued at $43,361,604.45. This trade represents a 3.43% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Roger Adsett sold 88,060 shares of the business's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $164.63, for a total transaction of $14,497,317.80. Following the completion of the sale, the chief operating officer directly owned 106,810 shares of the company's stock, valued at approximately $17,584,130.30. This trade represents a 45.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 179,777 shares of company stock worth $28,252,720. 2.10% of the stock is currently owned by insiders.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.